Submit Manuscript  

Article Details


A Novel Recombinant Multi-Epitope Vaccine Could Induce Specific Cytotoxic T Lymphocyte Response In Vitro and In Vivo

[ Vol. 24 , Issue. 6 ]

Author(s):

Yahong Wu, Wenjie Zhai, Meng Sun, Zhe Zou, Xiuman Zhou, Guodong Li, Zhongyi Yan, Yuanming Qi and Yanfeng Gao   Pages 573 - 580 ( 8 )

Abstract:


Background: Malignant tumor is still one of the important diseases worldwide, cytotoxic CD8+ T lymphocytes (CTLs) play an important role in killing tumor cells.

Objective: To enhance the immune response of our previously identified HLA-A2-restricted CTL epitopes, we designed a multiepitope YL66.

Method: The fusion protein GST-YL66 and DNA vaccine pcDNA3.1(+)-YL66 were used to induce CTLs from human peripheral blood mononuclear cells (PBMCs) of HLA-A*02+ healthy donors and and in HLA-A2.1/Kb transgenic(Tg) mice. and the activity of induced CTLs were tested by IFN-γ relesde ELISPOT assay and LDH cytotoxicity assay.

Results: GST-YL66 induced CTL could lysis tumor cells and release IFN-γ both in vitro and in vivo, and pcDNA3.1(+)-YL66 could also induce significant CTL response in vivo.

Conclusion: The designed fusion multiepitope YL66 could be used as a vaccine against patients with tumors expressing COX-2 and/or MAGE-4.

Keywords:

Cytotoxic T lymphocytes, vaccine, cancer immunotherapy, HLA-A2, epitope, YL66.

Affiliation:

School of Life Sciences, Zhengzhou University, Zhengzhou 450001, School of Life Sciences, Zhengzhou University, Zhengzhou 450001, School of Life Sciences, Zhengzhou University, Zhengzhou 450001, School of Life Sciences, Zhengzhou University, Zhengzhou 450001, School of Life Sciences, Zhengzhou University, Zhengzhou 450001, School of Life Sciences, Zhengzhou University, Zhengzhou 450001, School of Life Sciences, Zhengzhou University, Zhengzhou 450001, School of Life Sciences, Zhengzhou University, 100 Kexue Road, Zhengzhou 450001, School of Life Sciences, Zhengzhou University, 100 Kexue Road, Zhengzhou 450001

Graphical Abstract:



Read Full-Text article